 |
|
Dr. Armen Aprikian |
Dr. Armen Aprikian
Professor and Consultant
Head of Urology
Department of Surgery, College of Medicine
Director of Cancer Program, McGill University
Montreal, Canada
CURRICULUM VITAE
NAME: ARMEN G. APRIKIAN M.D., F.R.C.S.(C)
PLACE OF BIRTH: Alexandria, Egypt - May 20, 1962
CITIZENSHIP: Canada
MARITAL STATUS: Married, 1989 - Paola Kaprielian-Aprikian
CHILDREN: Saro Aprikian, born November 3, 1994
Alex Aprikian, born November 12, 1998
LANGUAGES: English, French, Armenian
BUSINESS ADDRESS: HOME ADDRESS:
Urology Department 7900 Jean Bourdon
Montreal General Hospital Montreal, Quebec H4K 1H3
1650 Cedar Avenue
Montreal, Quebec H3G 1A4
Phone: 514-934-8295
Fax : 514-934-8297
E-mail: armen.aprikian@muhc.mcgill.ca
EDUCATION:
Universite de Sherbrooke, Faculté de Medecine, Sherbrooke, QC 1981-1985
M.D. Medicinae Doctor
Vanier College C.E.G.E.P., Montreal, QC 1979-1981
D.E.C.: Diploma of Collegiate Studies, Health Sciences
POST-GRADUATE TRAINING:
Research:
Neuroendocrine differentiation of prostatic adenocarcinoma
Memorial Sloan-Kettering Cancer Center, New York, NY 1990-1992
Laboratory of Molecular Immunopathology
Urologic Oncology Laboratory
Supervisors: Victor E. Reuter, MD
Warren D. Heston, PhD
Carlos Cordon-Cardo, MD, PhD
Clinical:
Memorial Sloan-Kettering Cancer Center, New York, NY 1992-1993
Program Director: William R. Fair, MD
McGill University, Urology Residency Program, Montreal, QC 1987-1990
Program Director: Mostafa M. Elhilali, MD, PhD
Université de Sherbrooke, Sherbrooke, QC 1985-1987
Urology Program
Program Head: Michel Carmel, MD
MEDICAL LICENSURE & PROFESSIONAL CERTIFICATIONS:
American Board of Urology Certification 1996
Corporation Professionelle des Medecins du Quebec 1993
Specialist Certificate in Urologic Surgery
Certificate, Urologic Oncology, Memorial Sloan-Kettering Cancer Center 1993
Medical Permit, limited, New York State Education Department 1990-1994
Fellow of the Royal College of Physicians and Surgeons of Canada 1990
Specialty Certificate in Urologic Surgery
Certificate in Post Graduate Residency Training, Program in Urology 1990
McGill University, Montreal, QC
Medical Permit, Corporation Professionelle des Medecins du Quebec, #86-337 1986
Canadian Medical License, Medical Council of Canada, #62643 1986
APPOINTMENTS:
Full Professor with tenure, Department of Surgery, McGill University 2007-current
Chief (interim), Department of Oncology, McGill University Health Centre 2006-present
Head, Division of Urology, Department of Surgery, McGill University 2004-present
Urologist-in-Chief, McGill University Health Centre 2004-present
Associate Member, Department of Oncology, McGill University 2000-current
Associate Professor, Department of Surgery, Division of Urology, 1998-2007
Geographic University Full-Time, McGill University, Montreal
Program Director, Urology Residency Training Program 1998-2005
McGill University
Attending Surgeon, Urology, MUHC 1993-current
Attending, Department of Oncology, Montreal General Hospital 1993-current
Assistant Professor, Department of Surgery, Division of Urology 1993-1998 Geographic University Full-Time, McGill University, Montreal
Attending Surgeon, Department of Urology 1993-current
Royal Victoria Hospital, Montreal
Jewish General Hospital, Montreal
AWARDS AND SPECIAL HONOURS:
Everett C. Reid Award for Excellence in Teaching 2005
William Dawson Scholar, McGill University 2002-2009
Everett C. Reid Award for Excellence in Teaching 2002
American Foundation for Urologic Disease Practising Urologist Award 1998-1999
Everett C. Reid Award for Excellence in Teaching 1997
American Society of Clinical Oncology Young Investigator Award 1994-1995
Simon and Morris Fast Foundation Award 1993-1995 Montreal General Hospital Research Institute
$45,000.00 1st year : $15,000.00 2nd year : $15,000.00 3rd year
Canadian Urological Association Scholarship 1993-1994
Project Title: Clinical and Biological Implications
of Neuroendocrine Differentiation of Prostate Cancer, $30,000.00
Quebec Urological Association Research Contest 1989
First Prize, Basic Research
Project title: Gastric muscularis as a substitute urinary sphincter
First Class Honours, Health Sciences, Vanier College 1981
Bronze Medal, Canadian National Mathematics Contest 1978
Invited Lectures:
McGill University:
Department of Oncology, MUHC 2007
MUHC Cancer Care Mission Vision
Department of Oncology, Urologic Oncology Mini-Symposium 2007
Provincial biobank for prostate cancer
Department of Radiation Oncology 2006
Provincial outcomes for bladder cancer
Department of Medicine Grand Rounds 2005
Radical Cystectomy for invasive bladder cancer in Quebec:
Demographic trends and clinical outcome
Division of Geriatrics 2005
Evidenced-based management of prostate cancer
Departmental of Oncology, St. Mary’s Hospital 2005
Update on Hormone Refractory Prostate Cancer
Department of Surgery Grand Rounds 2005
Radical Cystectomy for invasive bladder cancer in Quebec:
Demographic trends and clinical outcome
McGill University Continuing Medical Education Rounds 2004
Prostate Cancer: Evidenced-based management
Department of Medicine Grand Rounds 2003
Can We Prevent Prostate Cancer?
McGill Cancer Centre 2002
Can we predict prostate cancer progression?
Department of Medicine Grand Rounds 2002
PSA and Prostate Cancer Early Detection, Where Do We Stand?
Department of Radiation Oncology
Andre Aisenstadt Memorial Clinical Day-Jewish General Hospital 2002
New Developments in prostate cancer management
McGill Department of oncology Retreat 2001
McGill Department of Surgery Grand Rounds 2000 Neobladder reconstruction after cystectomy: Where we are today
McGill Division of Geriatric Medicine 2000
New developments in the diagnosis and treatment of prostate cancer
in the elderly
McGill Department of Radiation Oncology 2000
Surgical management of localized prostate cancer
McGill Division of Nephrology 2000
Neuroendocrine differentiation, VEGF and prostate cancer progression
Bench to Bedside, Department of Experimental Surgery 1999
Neuropeptide-induced progression of prostate cancer
McGill Department of Endocrinology Grand Rounds 1999
Current concepts regarding biology of hormone-refractory prostate cancer
McGill Department of Radiation Oncology, MGH 1999
Impact of treatment-induced impotence on the quality of life of patients suffering
from prostate cancer
McGill Oncology Rounds 1998
Basic principles in prostate cancer biology
McGill Cancer Research Society 1997
Why not treat advanced prostate cancer with androgens?
McGill Department of Radiotherapy 1997
Molecular basis of androgen blockade
McGill Department of Experimental Surgery 1997
Biology of prostate cancer; bench to bedside
Department of Surgery Grand Rounds, Montreal General Hospital 1996
The surgical oncologist and testicular cancer
McGill Department of Oncology Grand Rounds 1996
The evolving role of surgery in NSGCT
Montreal General Hospital Endocrinology Rounds 1996
Hormonal therapy in prostate cancer
McGill Department of Nephrology Rounds 1995
The role of neuropeptides in the biology of prostate cancer
4th Annual Jewish General Hospital Urology CME Weekend 1995
Controversies in prostate cancer
McGill Department of Radiation Oncology 1995
Locally Advanced bladder cancer, current concepts
McGill University Lupus Group 1994 MESNA as uroprotectant in cyclophosphamide-induced hemorrhagic cystitis
Montreal General Hospital Medical Oncology Rounds 1994 Natural history of prostate cancer
McGill Urology Research Conference 1994
Neuroendocrine differentiation in prostate cancer
3rd Annual Jewish General Hospital, Urology Department CME Weekend 1994
Cytoreductive hormonotherapy in prostate cancer
Montreal General Hospital Radiation Therapy Department 1994
The role of surgery in the management of testis cancer
Montreal General Hospital Urology Nursing 1994
Basic concepts of prostate cancer and radical prostatectomy
McGill Uro-Oncology Research Group 1994
Clinical features of prostatic carcinoma
Radiation Oncology Department, McGill University 1993
The role of neoadjuvant hormonal therapy in prostate cancer
Outside McGill (bold designate international):
Multidisciplinary approach to invasive bladder cancer 2008
Canadian Urologic Association Scientific meeting, Edmonton
Penile and testicular cancer management in 2008 2008
Trois Rivieres Urology Group
Saudi Military Guard Hospital, Jeddah, Saudi Arabia 2008
Visiting professor in urologic oncology
Prostate cancer prevention-update
Canadian Association of Life Insurers Annual meeting, Montreal 2008
McMaster University, Division of Urology Visiting Professor 2008
NSAIDS and prostate cancer prevention
Radical cystectomy outcomes across Quebec
University of Alberta, Cancer Agency 2007
The Quebec Prostate Cancer Biobank
Nihzny Novgorod Ministry of Health, Russia 2007
MUHC Model of Cancer Care
Canadian Urology Association Annual Scientific meeting, Quebec City 2007
The use of 5-alpha reductase inhibitors in the management of men
at risk of prostate cancer
Gatineau Urology Group 2007
Management of complex urologic malignancies
2nd North American Congress on the Aging Male, Montreal 2007
Prostate Cancer Prevention
Quebec Urology Association 2006
Update from the AUA: kidney and testis cancer
Urology Associates of the South Shore 2006
Prevention of prostate cancer: adopt or not?
Verdun Family Doctors Group 2006
Prostatic Disease Management Update
The Canadian Armenian Business Council, Montreal 2006
What every man should know about the prostate
The Saudia Arabia Urology Society Annual Scientific Meeting, Jeddah 2006
Laparoscopic Radical prostatectomy for prostate cancer
Current issues in urologic surgical training
Biochemical failure after definitive local therapy for prostate cancer
Therapeutic Role of radical cystectomy for bladder cancer
Watchful waiting for prostate cancer: What are we watching and waiting for?
Canadian surgical wait times initiative, Toronto 2005
Impact of surgical delays on outcome after cystectomy for bladder cancer
La Lutte Contre le Cancer au Quebec Symposium on Prostate Cancer 2005
The role of watchful waiting in prostate cancer management
Universite de Sherbrooke 2005
Outcome after radical cystectomy in Quebec
The Canadian Urological Association annual meeting, Ottawa 2005
Combined androgen blockade for prostate cancer revisited
Cornell University Symposium on Radical Prostatectomy, New York 2005
Surgical outcomes after radical, laparoscopic and robotic prostatectomy
FRSQ Reseau Cancer: 6e Journee Scientifique, Quebec City 2005
The Quebec Prostate Cancer BioBank
The National Cancer Institute Prostate Cancer Initiative Bionet Meeting, Vancouver 2005
Non-steroidal anti-inflammatory use and prostate cancer risk
Survival after radical cystectomy in Quebec 2005
Trois Rivieres Urology Group
University of Miami, Miami, Florida
Current Problems in Urology 2005
Surgical tips in radical cystectomy
Quebec Urology Association 2004
UPM3 and prostate cancer detection
Surveillance for prostate cancer 2004
University of Manitoba, Division of Urology
Management of Biochemical failure after definitive therapy for localized prostate cancer 2004
University of Manitoba, Division of Urology
Combined Androgen Blockade in Prostate Cancer: Pro 2004
Quebec Urology Association, Urologic Oncology Update, Magog, Quebec
Prostate cancer update: New developments and impact on current practise 2004
Trois-Rivieres Urology Group, Trois-Rivieres, Quebec
Ups and Downs of PSA 2004
Canadian Association of Life Insurers Annual meeting, Montreal
Critical review of bisphosphonate therapy in men with prostate cancer 2004
Timing of androgen ablation in recurrent prostate cancer 2004
Mexican Urology Association annual meeting, Oaxaca, Mexico
Developments in prostate cancer diagnosis and prevention 2004
West-Island Family Physicians Group
Is Maximal Androgen Blockade dead? 2003 Universite de Laval, Quebec City
Management of bone metastases in prostate cancer 2003
Saskatchewan Cancer Agency, Saskatoon
Neuroendocrine differentiation, neuorpeptides and FAK in prostate
cancer progression 2003
Merck Frosst Laboratories, Montreal, Quebec
New Developments in Prostate Cancer 2003
Gilda’s Club Cancer Support Group, Montreal
Salvage Androgen Ablation in Prostate Cancer 2003
World Endourology Congress, Montreal
Quebec Urology Association Annual Meeting, Quebec City
Risk stratification in localized prostate cancer 2002
2nd Annual Urologic Oncology Update, Montego Bay, Jamaica
Debate: bladder sparing has a role in invasive bladder cancer: Con 2002
2nd Annual Urologic Oncology Update, Montego Bay, Jamaica
Hamilton Regional Cancer Centre Grand Rounds 2002
What to do in High-risk localized prostate cancer?
Southern Ontario Urology Group, Toronto 2002
What’s new in hormonal therapy of prostate cancer?
Surgical tips to improve results with radical prostatectomy 2002
Prostate cancer update, Nassau, Bahamas
What to do with recurrent prostate cancer? 2002
Prostate cancer update, Nassau, Bahamas
Uro-Rive Nord 2002
Prostate cancer invading the seminal vesicles
Current management of metastatic testicular cancer 2002
Charles Lemoyne Hospital Department of Oncology Rounds
Changes in Urologic Surgical Training 2002
Canadian Academy of Urologic Surgeons, St. John’s, Newfoundland
Early androgen ablation for rising PSA after definitive therapy for prostate cancer 2002
Canadian Section of the Societe Internationale d’Urologie
Stockholm, Sweden
Bisphosphonate therapy in prostate cancer 2002
Montreal Novartis Advisory Board
Management of bladder cancer 2002
Group d’etude en oncology du Quebec (GEOQ)
Advanced prostate cancer therapy 2002
Northern Ontario Urology Society, Sudbury
The role of cystectomy in recurrent superficial bladder cancer 2002
Quebec Urology Association Annual Meeting, Montreal
The surgical management of renal cancer 2001
Canada-Mexico Urologic Oncology Update, Ixtapa, Mexico
Translational research opportunities in prostate cancer 2001
Canada-Mexico Urologic Oncology Update, Ixtapa, Mexico
Watchful Waiting for Prostate Cancer:
What are we watching with and what are we waiting for? 2001
Dalhousie University Urology Department
Hormone-refractory prostate cancer, update 2001
West-Island Prostate Cancer Support Group, Montreal
West-Island Prostate Cancer Support Group, Montreal
The role of early androgen ablation in p3 N+ prostate cancer 2000
Urologists of the Rive-Nord and Outaouais 4th Annual Meeting
Controversies in Prostate Cancer-The role of early hormonal therapy 2000
Nassau, Bahamas
AUA Update on Prostate and Kidney cancer 2000
Quebec Urological Association, Chateau Bromont, Quebec
Association des Urologues Rive-Nord 2000
Panel on prostate cancer case discussion
Château Tremblant, Quebec
The role of surgery in advanced bladder cancer 2000
Update in Renal and bladder cancer management
Quebec City
Prostate Cancer from diagnosis to treatment: Canadian perspective 2000
Societe Internationale d’Urologie Satellite symposium, Singapore
Challenging cases in Urology, prostate and bladder cancer panel member 1999
Miami, Florida Treatment of BCG-refractory superficial TCC of the bladder 1999
Jewish General Hospital Continuing Education Retreat, Quebec City
Gender Health Lecture Series 1999
Impact of Prostate cancer therapy on quality of life
Quebec Cancer Society, Montreal 1999
Current treatment of clinically localized prostate cancer
Canadian Urological Nursing Association, Montreal 1999
Demystifying prostatic disease
Canadian Urological Association Annual Meeting 1999
Update from the AUA on prostate cancer
The role of RPLND in stage 1 NSGCT-debate 1999
Carling Lake, Quebec
Neuropeptide and VEGF signalling in the progression of human prostate cancer 1999
Maisonneuve-Rosemont Hospital, CHUM, Research Institute
Workshop on early prostate cancer; predictors of progression 1998
University of Miami, Florida
Innovators in Urology meeting, London, UK
Prostate Cancer Support Group, Montreal 1998
What’s new in prostate cancer therapy
Urological Association of Morocco Annual Meeting 1998
Workshop on testicular cancer
The clinical significance of neuroendocrine differentiation of prostate cancer:
From laboratory to bedside
Canadian Forum on Prostate Cancer 1997
Progression to androgen independent disease
Quebec Urological Association Semi-Annual Meeting, Magog 1997
Update on Urologic Oncology from the AUA
Montpellier, Nimes and McGill University Urology Departments, Nimes, France 1997 Workshop in bladder cancer
Urologic Oncology Update, T1 bladder cancer deserves more respect 1997
Quebec Urological Association, Carling lake, Quebec
Neoadjuvant Endocrine therapy in localized prostate cancer 1997
Brazilian Urology Congress, Brazil
Urologic Oncology Update Hormone-refractory prostate cancer 1996
Dalhousie University, Department of Urology, Halifax 1996
The role of bombesin/GRP in the rpogression of prostate cancer.
What to do with post-chemotherapy residual mass in testis cancer?
Universite de Sherbrooke, Departement d'Urologie 1995
Non-seminomatous germ cell tumours; current surgical concepts
Calgary Urologic Oncology Group 1995
Neoadjuvant cytoreductive hormone therapy in prostate cancer
Prostate Cancer Workshop; Treatment of localized prostate cancer 1995
Canadian Association of Radiation Oncologists/Royal College, Montreal 1995
Clinical use of serum PSA : A urologist's perspective
Northeastern American Urological Association Meeting, Luxor, Egypt 1995
Current concepts in hormone-refractory prostate cancer
Abbott Urology Update, Blue Mountain, Ontario 1994
Neoadjuvant therapy in prostate cancer
Uromed Associates Annual Meeting 1994
Genetics of prostate cancer
Universite de Sherbrooke, Departement d'Urologie 1994
Clinical implications of neuroendocrine differentiation in prostate cancer
Quebec Association of Radiologists 1994
Moderator-Use of ultrasound in prostatic and breast diseases
Zeneca Urology Update-Moncton, New Brunswick 1994
Current concepts regarding neoadjuvant endocrine therapy in clinically
Lakeshore General Hospital, Department of Surgery and Anesthesia Rounds 1994
The role of the surgical oncologist in the germ cell tumours management
Montreal Support Group for Patients with Prostate Cancer 1993
Visiting Professorships:
Military Guard Hospital, Jeddah, Saudi Arabia 2008
University of Alberta, Department of Oncology 2007
Nihzny-Novgorod Regional Ministry of Health, Russia 2007
Queen’s University, Department of Urology 2007
University of Western Ontario, Department of Urology 2005
Universite de Sherbrooke, Departement d’Urologie 2005
University of Manitoba, Department of Urology 2004
Universite de Laval, Department of Urology, Quebec City 2003
Hamilton Regional Cancer Centre, Radiation Oncology Department 2002
Dalhousie University, Dept of Urology, Halifax 2001
Sao Paulo University Department of Urology, Sao Paulo, Brazil 1997
Dalhousie University, Dept Urology, Halifax 1996
OTHER CONTRIBUTIONS
US Department of Defense, invited consultant on research funding direction 2008
ProCure Alliance, Quebec Prostate Cancer Foundation 2001-current
Founding member of Board of Directors
Chair, Procure Biobank committee
Chair, Quebec Prostate Cancer Biobank Network
Royal College of Physicians and Surgeons of Canada Nucleus Committee Member 2004-current
Vice Chairman, Royal College of Canada, Urology Examination 1998-2000
Royal College of Physicians and Surgeons of Canada Exam Board member-Urology 1996-2000
Quebec College of Specialists-Examiner in Urology 1997-1998
McGill University Internal Review Principal Surveyor 2004
Editorial Boards:
1) Prostate Cancer and Prostatic Diseases 2000-current
2) Our Voice 2005-current
3) World Journal of Urology 2005-current
4) Canadian Urology Association Journal, section editor 2007-current
Invited Ad Hoc Reviewer:
2) International Journal of Cancer,
4) Biochemistry and Cell Biology
5) Canadian Journal of Urology
6) Cancer Detection and Prevention
7) Cancer
8) Experimental and Molecular Pathology
9) Prostate
11) World Journal of Urology
12) Canadian Medical Association Journal
13) Urology
Grant reviewer:
1) FRSQ Chercheur Boursier-Clinicien
2) MRC – CIHR operating grants
3) Canadian Prostate Cancer Research Foundation
4) Kidney Foundation of Canada
5) Canadian Urological Association
Canadian Prostate Cancer Research Foundation Scientific Advisory Board 2005-current
Grant review panel member
Canadian Hereditary Breast and Ovarian Cancer Guidelines Task Force 2004
Scientific Officer, NCIC Prostate Cancer Research Initiative Ideas Grant 2002
Member Management Committee of the NCIC Prostate Cancer Research Initiative 2001-2006
Medical Advisory Board of the Canadian Prostate Cancer Research Fund 1997-current
Medical Advisory Board of the Kidney Foundation of Canada 1998-2000
Medical Advisory Committee, Cedars Cancer Institute 2006-current
External Reviewer for Conseil de l’Evaluation Technologie du Quebec 1999
evaluation on Brachytherapie for prostate cancer
Member, Surgical Scientist Program, Division of Experimental Surgery 1999-current
Dept. of Surgery, McGill
Ad Hoc Reviewer for University Promotion:
University of Western Ontario
Full Professor Department of Surgery application, Dr. Gerald Brock. 2002
Dalhousie University
Associate Professor, Department of Surgery, Dr. Ricardo Rendon 2005
University of Toronto
Associate Professor of Surgery, Dr. Robert Nam 2005
University of Oklahoma 2007
Associate Professor of Surgery, Dr. Carson Wong
Mashdots Foundation of the Armenians From Egypt Association-
Founding Board Member 2005-current
(provides bursaries to university students in Armenia)
Administrative Responsibilities:
Committees:
Programme Quebecois de lutte contre le cancer, accreditation committee 2007-current
Dean’s Committee on McGill RUIS Oncology 2007-2008
Royal College Specialty Committee Urology – Vice Chairman 2007
Chair (Interim), MUHC Oncology Mission 2006-current
Head (Interim), MUHC Department of Oncology 2006-current
MUHC-CHUM Complementarity Committee in Oncology 2006
Medical Advisory Committee, Cedars Cancer Institute 2006-current
McGill RUIS Table d’Oncologie 2006-current
Medical Advisory Committee, MUHC 2006-current
Canadian Urology Association Executive Committee Member 2005-2008
Canadian Urology Association Guidelines Committee Member 2005-2008
McGill Department of Surgery Performance Evaluation Committee 2005-2007
Chairman of Board of Directors, McGill Urology Associates 2004-present
MUHC Surgical Services Executive Committee 2004-current
McGill Department of Surgery Executive Committee 2004-current
Royal College of Physicians of Canada, Urology Nucleus Committee 2004-2007
MUHC Department of Oncology Executive Committee 2004-2006
Canadian Bioresearch Network in Prostate Cancer 2003-current
Chair, Scientific Program Committee, Canadian Urological Association 2002-2003
NorthEastern American Urological Association By-Laws Committee 2002-2006
McGill University Department of Surgery Adair Chair Search Committee 2002-2004
President, Canadian Academy of Urologic Surgeons 2002-2003
McGill University Department of Surgery Chair search committee 2002-2004
Head, McGill Oncology GU Network 2001-2003
Member of NCIC Prostate Cancer Research Initiative Management Committee 2001-2006
ProCure Alliance, Quebec Prostate Cancer Foundation 2001-current
Founding member of Board of Directors
Chair, Procure Biobank committee
Chair, Quebec Prostate Cancer Biobank Network
McGill Prostate Cancer Research Foundation Committee 2000-current
Violence in the workplace-Operating room committee-MGH 1999-2000
Program Director, McGill Urology Residency Training Program 1998-2004
McGill Faculty Postgraduate Medical Education Committee 1998-2004
Quebec Urological Association Executive Committee member 1997-2000
McGill Department of Surgery Surgical Scientist Program 1998-current
Quebec College of Physicians Guidelines Committee on PSA Use 1997-1998
Canadian Cancer Society Prostate Cancer Forum Organizing Committee 1996-1997
McGill Urology Training Program Committee 1996-current
Canadian Urologic Oncology Group Executive Committee 1996-1999
Quebec Urological Association Continuing Medical Education Committee 1994-1997
McGill Urology In-Training examination committee 1994-current
McGill Urology Research Committee 1994-current
McGill Urology Resident Training Program committee for the establishment of 1993
Training objectives Head: Jaques Corcos, MD
Professional Memberships:
Canadian Prostate Bioresearch Network 2003-
American Urological Association, Active Member 1995-
Canadian Academy of Urological Surgeons 1995-
American Board of Urology 1995-
Societe Internationale d’Urologie 1995-
American Association for Cancer Research 1994-2000
American Society of Clinical Oncology 1994-
Canadian Urologic Oncology Group 1994-
Northeastern Section, American Urological Association, Active Member 1994-
Quebec Urologic Association 1993-
Federation des Medecins Specialistes du Quebec 1993-
Canadian Urologic Association 1991-
Royal College of Physicians and Surgeons of Canada 1990-
Armenian Medical Association of Quebec 1988-
Canadian Medical Association 1986-
Quebec Medical Association 1986-
Association of Interns and Residents of Quebec, past member 1985-1990
Scientific Meeting Session Moderator:
Canadian Urology Association Annual Meeting, Montreal 2007
Session on prostate cancer
Quebec Urological Association Annual Meeting 2005
Session on basic and clinical research
Session on urologic oncology
Societe Internationale d’Urolgie, Honolulu, Hawaii 2004
Session on prostate cancer research
NorthEastern Section American Urological Association Annual Meeting, Halifax, NS 2003
Novartis Symposium on Bisphosphanates and Androgen Ablation for Prostate Cancer 2003
Hotel Vogue, Montreal
Quebec Urological Association Annual Meeting 2003
Session on basic and clinical research
Bladder Cancer, 2nd Annual Urologic Oncology Update, Montego Bay, Jamaica 2002
Canadian Urologic Association Annual Meeting, St. John’s, Newfoundland 2002
Prostate cancer podium session
Societe Internationale d’Urologie session on prostate cancer biology 2002
Stockholm, Sweden
Quebec Urological Association Annual Meeting 2002
Session on basic and clinical research
Canadian Urological Association Annual Meeting, Basic Science poster session 2001
Toronto, ON
Quebec Urological Association Annual Meeting 2001
Testis cancer session
Panel discussion moderator on screening for prostate cancer 2001
Quebec Urology Association Annual Meeting, Montreal 2001
Socitete Internationale d’Urologie session on prostate cancer biology 2000
Singapore
Quebec Urological Association Annual Meeting, Quebec City 2000
Canadian Urological Association Annual Meeting, London, ON 1999
AUA update on prostate cancer
Canadian Urologic Association Annual Meeting, London, ON 1999
Scientific session on prostate cancer
Quebec Urological Association Annual Meeting, Montreal 1999
Canadian Urologic Association Annual Meeting, Halifax, NS 1998
Scientific session on prostate and testis cancer
International Society of Urology 1997
Scientific session on advanced prostate cancer
Scientific session on urologic oncology
Quebec Urologic Association Annual Meeting, Montreal 1996
Scientific session on basic prostate cancer research
Quebec Urologic Association Annual Meeting, Montreal 1995
Scientific session on prostate cancer research
Panel member, Bladder Cancer Update
Quebec Urologic Association Annual Meeting, Quebec City 1994
Scientific session on prostate cancer research
Member of Scientific Meeting Organization Committees:
29th Annual Societe Internationale d’Urologie meeting, Paris, france 2007
Abstract review committee
6th Annual Canadian Senior Resident Urologic Oncology Course 2006
Course Co-Director, Montreal
5th Annual Canadian Senior Resident Urologic Oncology Course 2005
Course Director, Montreal
4rth Annual Canadian Senior Resident Urologic Oncology Course 2004
Course Director, Montreal
27th Annual Societe Internationale d’Urologie meeting, Honolulu, Hawaii 2004
Abstract review committee
Co-Chairman, Scientific Program, Canadian Urological Association Annual Meeting 2003
Montreal
Chairman, Canadian Academy of Urology Annual meeting, Montreal. 2003
Chairman, McGill Prostate Cancer Satellite Symposium 2003
Sienna, Italy
3rd Annual Canadian Senior Resident Urologic Oncology Course 2003
Course Director, Montreal
2nd Annual International Urologic-Oncology Update 2002
Montego Bay, Jamaica
Chairman, SIU Canadian delegation satellite meeting, Stockholm, Sweden 2002
2nd Annual Canadian Senior Resident Urologic Oncology Course 2002
Course Director, Montreal
Co-Chairman, St. Lawrence Urology Group 7th Annual Meeting 2001
Magog, Quebec
Northeastern Section AUA scientific committee, Boca Raton, Florida 2001
Canadian Senior Resident Urologic Oncology Course 2001
Course Director, Montreal
Scientific Committee-North Eastrern Section of American Urological Association 2000
Annual Meeting, Boca Raton, Florida
Chairman, SIU Canadian delegation satellite meeting
“Prostate Cancer in Canada, from diagnosis to treatment”, Singapore 2000
Chairman, Joint Canada-Brazil Urologic Oncology Update 1998-1999
Brazilian Urological Congress, Rio de Janeiro, Brazil
Chairman, McGill Continuing Medical Education Scientific meeting 1998-1999
Salvador, Bahia, Brazil
Innovators in Urology International Meeting, member of steering committee 1998
Quebec Urologic Association Annual Meeting, Quebec City 1997
Canadian Cancer Society Prostate Cancer Forum, Toronto 1996-1997
Canadian Urologic Association Annual Meeting, scientific committee 1996-1997
Northeastern Section American Urological Association Annual Meeting 1996-1997 abstract selection committee
McGill University Department of Urology Research Day 1996-1997
Quebec Urologic Association Annual Meeting, Montreal 1996
Quebec Urological Association Annual Meeting, Montreal, November 1995
Organization of Quebec Urologic Assocaition annual scientific meeting, Quebec City 1994
Research Prize Selection Committee:
Canadian Urology Association 2004
St. Lawrence Urology Group Annual Meeting, Magog, Quebec 2004
Canadian Urology Association 2003
St. Lawrence Urology Group Annual Meeting, St. Adele, Quebec 2003
St. Lawrence Urology Group Annual Meeting, St. Adele, Quebec 2002
Quebec Urologic Association Annual Meeting, Quebec City 1997
Quebec Urologic Association Annual Meeting, Montreal 1996
Quebec Urologic Association Annual Meeting, Montreal 1995
Quebec Urologic Association Annual Meeting, Quebec City 1994
RESEARCH ACTIVITIES
Basic Research Activities:
1) Clinical and biological implications of neuroendocrine differentiation of
prostatic adenocarcinoma.
2) The role of bombesin/gastrin-releasing peptide and other neuropeptides
in the biology of prostate cancer
3) Focal adhesion kinase (FAK) and prostate cancer metastasis
4) Molecular characterization of prostatic carcinoma
Clinical Research Activities:
1) The relationship of family cancer history and prostatic carcinoma.
2) Quality of life after radical prostatectomy for prostate cancer
3) Operative delay and prognosis in transitional cell carcinoma of the
bladder
4) Clinical epidemiology of prostate cancer in Quebec
5) Natural history of prostatic carcinoma
6) Non-steroidal anti-inflammatories and prostate cancer risk
7) Surgical volume and clinical outcome in urologic oncology
Research Funds:
Personal Salary Support (peer-reviewed):
McGill William Dawson Award : $10,000 per year x 7 2001-2009
Fonds de la Recherche en Sante du Quebec (FRSQ) Bourse Chercheur 2001-2005
Clinicien Senior : $50,000 per year x 4
Fonds de la Recherche en Sante du Québec (FRSQ) Bourse Chercheur 1997-2001 Clinicien Junior-2 : $40,000 per year x 4
Clinicien Junior-1 : $30,000 per year x 3
Kidney Foundation of Canada Scholarship 1994-1996
Value: $45,000 per year x 2 Awarded: $16,000 per year x 2
Canadian Urological Association Scholarship, awarded, not accepted 1994-1995
Independent Operating Funds as Principal Investigator (peer-reviewed):
Canadian Urologic Oncology Group Grant - $10,000 2004-2005
Operative delay and clinical outcome in bladder cancer
US Department of Defense – US $307,000 2004-2006
NSAID and prostate cancer risk and prognosis
Canadian Institutes of Health : $87,000 per year x 2 (declined) 2004-2005
NSAID and prostate cancer risk and prognosis
(ranked first in panel of 27 applications)
Focal Adhesion Kinase activation in the progression of human prostate cancer 2003-2005
Kidney Foundation of Canada : $50,000 per year x 2
Neuropeptides and progression of human prostate cancer 2003-2004
Canadian Prostate Cancer Research Foundation : $50,000 per year x 2
McGill William Dawson Award : $15,000 per year x 5 2002-2007
Focal Adhesion Kinase activation in the progression of human prostate cancer 2002-2003
Canadian Prostate Cancer Research Foundation : $50,000 per year
GRP in the progression of prostate cancer 1999-2001
Kidney Foundation of Canada : $50,000 per year
Focal Adhesion Kinase activation in the progression of human prostate cancer 1999-2001
Canadian Prostate Cancer Research Foundation : $50,000 per year x 2
American Foundation for Urologic Disease 1998-1999
Project entitled “Bombesin/GRP in the metastatic progression of human prostate cancer : US $5,000
GRP in the progression of prostate cancer 1997-1999
Kidney Foundation of Canada : $50,000 per year
Bombesin family of neuropeptides and androgen-independent prostate cancer 1996-1997
Kidney Foundation of Canada : $40,000
Kidney Foundation of Canada 1994-1996
The role of neuropeptides in the biology of prostate cancer :
$40,000 per year x 2
Fonds de la Recherche en Sante du Quebec (FRSQ) Bourse d'Etablissement 1994-1995
de Jeune Chercheur : $20,000
Co-Principal Investigator Operating Funds (peer-reviewed):
$280,000 per year x 3
PI: Marie-Elise Parent, PhD
$350,000 per year x 3
PI: Marie-Elise Parent, PhD
CHIR-Androgen receptor gene polymorphisms in prostate cancer 2002-2004
PI: Mark Trifiro, MD
Canadian Urologic Oncology Group 1995-1996
Quality of life in patients with localized prostate cancer.
$5,000 awarded to Dr. P. Karakiewicz
Fonds de la Recherche en Sante du Quebec - Quebec Family Cancer Network 1995-1996 (No direct funds)
Fonds de la Recherche en Sante du Quebec - Prostate Cancer Research Network 1994-1997
$50,000 per year x 2
Clinical Trial Management:
Procure-FRSQ Quebec Prostate Cancer Biobank 2006-
Principal Investigator
High-dose bicalutamide in men with hormone-refractory prostate cancer 2006-2007
Principal Investigator 2004-2006
Phase I/II trial of intravesical monoclonal antibody targeting cell-adhesion molecule
instillation for BCG-refractory transitional cell carcimoma of the bladder
Principal Investigator 2003-2005
Phase II trial of Iressa in patients with rising PSA after radical prostatectomy for
prostate cancer
Principal Investigator for Canada
EORTC-Intergroup/NCIC Randomized controlled trial of adjuvant chemotherapy 2003-2008
After radical cystectomy for muscle-invasive transitionl cell carcinoma of the bladder
Randomized controlled trial of tamoxifen to reduce the incidence of gynecomastia
in men treated with casodex monotherapy for prostate cancer
Principal Investigator 2001-2007
Phase II study of UPm3 urinary prostate cancer detection test in men undergoing
prostate biopsy
Principal Investigator 2000-2001
Phase III randomized study of DFMO in superficial bladder cancer
Co-Principal Investigator (Dr. Marc Trudeau) 1999-2001
Phase II trial of Carboplatin and Gemcitabine in metastatic TCC of the bladder
Principal Investigator 1998-2000
Phase III randomized placebo-controlled trial of zoledronate in hormone refractory
bone metastatic prostate cancer
Co-Principal Investigator (Dr. Marc Trudeau) 1998-2000
Phase II trial of chemohormonal therapy in stage D2 prostate cancer
Principal Investigator 1997-1998
Phase II randomized double blind multicentre study evaluating liarozoile at three
different doses in patients with prostate cancer failing with rising PSA
Principal Investigator 1996-1997
Phase III randomized study comparing 3 versus 6 months of neoadjuvant hormonal therapy in clinically localized prostate cancer
Principal Investigator 1995-1997
Phase III study of immunocytology and ploidy in patients with bladder cancer. Study sponsored by NCI-USA Bladder Cancer Marker Network
Co-Principal Investigator 1994-1997
Development of RT-PCR assays for the detection of metastatic disease in patients with prostate cancer
Other investigators: Dr. Wilson Miller and Dr. Michel Bazinet
Principal Investigator 1994-1996
Phase III study of oral bropirimine versus intravesical BCG in adult patients
with BCG naive bladder carcinoma in situ
Upjohn Company, protocol # M/1600/0015, Montreal General Hospital
Principal Investigator 1994-1995
Phase II study of oral bropirimine in adult patients with BCG-resistant bladder
carcinoma in situ or with bladder carcinoma in situ and intolerance to BCG
Upjohn Company, protocol # M1600/0015, Montreal General Hospital
Industry Medical/Scientific Advisory Board Member:
AstraZeneca Canada
Novartis
Sanofi-Synthelabo
Proscan Pharma
H3 Pharma
GSK
Wyeth
Grant Thornton UK
PUBLICATIONS: (Underlined names are students, residents, or fellows under my direct supervision)
Peer Reviewed Publications (N= 88):
First author: 14
Senior Author: 31
(88) Amin, M, Jeyaganth, S, Fahmy, N, Bégin, LR, Aronson, S, Jacobson, S, Tanguay, S, Kassouf, W, Aprikian, AG.
Dietary habits and prostate cancer detection: a case control study.
Submitted, Canadian Urology Association Journal, 2008.
(87) Abou-Youssif, Kassouf W, Steinberg J, Aprikian AG, Laplante MP, Tanguay S.
Active surveillance for selected patients with renal masses: updated results with long-term follow-up.
Cancer, Sep 1;110(5):1010-4, 2007
(86) Androgen-receptor CAG repeat length contraction in diseased and non-diseased prostatic tissues.
Sircar K, Gottleib B, Alvardo C, Aprikian AG, Beitel LK, Alam-Fahmy M, Begin LR, Trifiro M.
Prostate Cancer Prostatic Diseases, 10:360-368, 2007.
(85) An analysis of pre-operative delays prior to radical cystectomy for bladder cancer in Quebec.
Fahmy, N, Kassouf, W, Jeyaganth, S, Amin, M, Steinberg, J, Tanguay, S, Mahmud, S, Aprikian, A.G.
Canadian Urology Association Journal, 2:102-110, 2008
(84) Amin, M, Jeyaginth, S, Fahmy N, Aronson, S, Jacobsen, S, Tanguay, S, Aprikian, A.G.
Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia and atypical small acinar proliferation.
Canadian Urology Association Journal, 1:245, 2007
(83) Trachtenberg J, Bogaards A, Gertner M, Weersink R, C.Yue, J. Savard, Evans A, McLusky S, Haider M, Aprikian AG, Wilson BC and Elhilali M.
Vascular-Targeted Photodynamic Therapy with Palladium-Bacteriopheophorbidephotosensitizer for Recurrent Prostate Cancer Following Definitive Radiation Therapy: assessment of saftety and treatment response.
Journal of Urology, September 2007
(82) Wang Jia-Chi, Bégin L.R., Bérubé N.G., Chevalier S., Aprikian A.G., Gourdeau H. Chevrette M.
Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications.
Clinical Cancer Research, 13:2354, 2007.
(81) Ezer H., Ricard N., Bouchard L., Souhami L., Saad F., Aprikian A., Taguchi Y.
Adaptation of wives to prostate cancer following diagnosis and 3 months after treatment: A test of family adaptation theory.
International Journal of Nursing Studies, 43:827-838, 2006
(80) Sircar K., Gaboury L., Ouadi L., Mecteau M., Scarlata E., Saad F., Aprikian, A.G., Tanguay S., Lapointe S., Lussier C., Miletti T., Lanoix J.
Isolation of human prostatic epithelial plasma membranes for proteomics using mirror image tissue banking of radical prostatectomy specimens.
Clinical Cancer Research, 12:4178-4184, 2006
(79) Chen G., Sircar K., Aprikian A.G., Potti A., Goltzman D., Rabbani SA.
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.
Cancer. 107:289-298, 2006.
(78) Fahmy, N., Mahmud, S., Aprikian, A.G.
Delay in the surgical treatment of bladder cancer and survival: systematic review of the literature.
European Journal of Urology, 50(6):1176-82, 2006.
(77) Zorn, K., Fong, B., Taguch, Y., Aprikian, A.G.
Urology resident perception of participation in radical prostatectomy.
Canadian Journal of Urology, 13:3164-3168, 2006
(76) Alvarado C, Beitel LK, Sircar K, Aprikian AG, Trifiro M, Gottlieb B.
Somatic mosaicism and cancer: A micro-genetic examination into the role of the androgen receptor in prostate cancer
Cancer Research, 65:8514-8518, 2005
(75) Mahmud S, Fong B, Fahmy N, Tanguay S, Aprikian AG.
Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec: a population-based study
Journal of Urology 175:78-83, 2006
(74) Mahmud S, Tanguay S, Franco E, Begin LR, Aprikian AG.
Contribution of microcell-mediated chromosome transfer toward our understanding of prostate cancer progression.
In press, 2007
(72) Karakiewicz PI, Benayoun S, Kattan MW, Perrotte P, Valiquette L, Scardino PT, Cagiannos I, Heinzer H, Tanguay S, Aprikian AG, Huland H, Graefen M.
Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen.
Journal of Urology, 173:1930-4, 2005
(71) Kassouf W, Aprikian AG, Laplante M, Tanguay, S.
Natural history of renal masses followed expectantly.
Journal of Urology, 171:111-3, 2004
(70) Chen G., Shukier N., Potti A., Sircar K., Aprikian A, Goltzman D., Rabbani S.
Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.
Cancer, 101:1345-1356, 2004
(69) Kassouf W., Ismail HRA, Aprikian, AG, Chevalier, S.
Whole-mount prostate sections reveal differential endoglin expression in stromal, epithelial, and endothelial cells with the development of prostate cancer.
Prostate Cancer and Prostatic Diseases 7:105-110, 2004
(68) Karakiewicz PI, Tanguay S, Kattan MW, Elhilali MM, Aprikian, AG.
Erectile and urinary dysfunction after radical prostatectomy for prostate cancer in Quebec: a population-based study of 2415 men.
European Journal of Urology, 46:188-94, 2004
(67) Ozdal O., Aprikian, A.G., Begin, L.R., Behlouli, H., Tanguay, S.
Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer
British Journal of Urology International, 93:970-974, 2004.
(66) Fradet Y, Saad F., Aprikian A.G., Dessureault J., Elhilali M.M., Trudel C., Masse B., Piché L., Chypre C.
Upm-3, a new urinary molecular diagnostic test for prostate cancer detection.
Urology, 64:311-315, 2004.
(65) Ross P., Mahmud S., Stephensen A., Souhami L., Tanguay S., Aprikian A.G.
Variations in PSA doubling time in patients with prostate cancer on watchful waiting:
The value of PSA doubling time short-term determinations.
Urology, 64:323-328, 2004.
(64) Zoubeidi A., Aprikian A.G., Chevalier S.
F-actin as a tyrosine phosphorylated partner of the Fer tyrosine kinase in human prostate
cancer cells
In revision, Journal of Biologic Chemistry, 2004
(63) Mahmud S., Franco E., Aprikian A.G.
Prostate Cancer and Use of Non-Steroidal Anti-Inflammatory Drugs:
Systematic Review and Meta-Analysis
British Journal of Cancer, 90:93-99, 2004
(62) Ismail H.A., Altaweel W., Chevalier S., Kassouf W., Aprikian A.G.
Expression of VEGF-A in human prostate cancer lymph node metastases
Canadian Journal of Urology, 11:2146-50, 2004
Bazinet M., Scardino P., Aprikian A.G.
Comorbidity and socioeconomic status may confound the relation between treatment and
health-related quality-of-life in men treated with prostatectomy for prostate cancer
In revision, American Journal of Clinical Epidemiology, 2004
(60) Lacoste J., Aprikian A.G., Chevalier S.
Focal Adhesion Kinase is required for bombesin-induced prostate cancer cell motility
Molecular and Cellular Endocrinology, 235: 51-61, 2005
(59) Aprikian A.G., Fleshner N., Langleben A.
An oncology perspective on the benefits and costs of total androgen blockade in metastatic
prostate cancer
Canadian Journal of Urology, 10:1986-94, 2003
(58) Al-Otaibi, M., Al-Taweel, W., Bin-Saleh, S., Herba, M., Aprikian, A.G.
Disseminated intravascular coagulation following transrectal ultrasound biopsy of the prostate.
Journal of Urology, 171:346, 2004.
(57) Kassouf W., Tanguay S., Aprikian A.G.
Nilutamide as second-line anti-androgen therapy for prostate cancer after androgen ablation fails.
Journal of Urology, 169:1742-44, 2003
(56) Ismail H., Pollak M., Behlouli H., Tanguay S., Bégin L., Aprikian A.G.
Serum insulin-Like growth factor-1 and IGF-binding protein-3 do not correlate with adverse pathologic features in patients undergoing prostate biopsy
British Journal of Urology International, 92:699-702, 2003
(55) Karakiewicz P., Kattan M., Tanguay S., Bazinet M., Elhilali M., Scardino P., Aprikian A.G.
Cross-cultural validation of the UCLA prostate cancer index
Urology, 61:302-7, 2003
(54) Karakiewicz P.I., Kattan M., Foulkes W., Tanguay S., Scardino P., Elhilali M.,
Aprikian A.G.
Familial prostate and breast cancer in men treated with postatectomy for prostate cancer:
population based case-control study
Journal of Urology, 169:240-244, 2003
(53) Stephenson A., Aprikian A.G., Jacobsen A., Souhami L., Elhilali M., Tanguay S.
Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer
Urology, 59:652-656, 2002
(52) Ismail H., Pollak M., Behlouli H., Tanguay S., Bégin L., Aprikian A.G.
Insulin-like growth factor-1 and IGF-binding protein-3 in the detection of prostate cancer in
men undergoing prostate biopsy
Journal of Urology, 168, 2426-30, 2002
(51) Andonian S., Rabah D., Aprikian A.G.
Pseudomonas Aeroginosa sacroileitis and osteomyelitis of pelvic bones after radical
prostatectomy
Urology, 60;698, 2002
(50) David M., Souhami L., Aprikian A.G.
Post-renal acute renal failure during pelvis irradiation for prostate cancer
Canadian Journal of Urology, 9:1497-1499, 2002
(49) Chevalier S., Defoy I., Lacoste J., Hamel L., Guy L., Begin L.R., Aprikian A.G.
VEGF and signaling in the prostate: More than angiogenesis
Molecular and Cellular Endocrinology, 189:169-179, 2002
(48) Tanguay S., Begin L.R., Elhilali M., Behlouli H., Karakiewicz P., Aprikian A.G.
Comparative evaluation of total PSA, free/total PSA ratio and complexed PSA in prostate
cancer detection
Urology, 59:261-265, 2002
(47) Ismail H., Landry F., Aprikian A.G., Chevalier S.
Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate
Prostate, 51:117-125, 2002
(46) Lo C., Wong C., Al-Said N., Emond J., Aprikian A.G.
Natural History of Seminoma: A Case Report
Canadian Journal of Urology, 8:1234-1236, 2001
(45) El-Taher O, Behlouli H., Chevalier S., Aprikian A.G.
Relationship between P21 protein expression and prognosis in advanced prostate cancer
treated by androgen ablation
Prostate, 49:191-199, 2001
(44) Allard P., Zoubeidi A., Nguyen, L.T., Tessier S., Tanguay S., Chevrette, M., Aprikian A.G.,
Chevalier S.
Links between Fer tyrosine kinase expression and prostate cell proliferation
Molecular and Cellular Endocrinology 159:63-77, 2000
(43) Allard P., Beaulieu P., Aprikian A.G., Chevalier S.
Bombesin modulates the association of Src with a nuclear 110 kDa protein expressed in dividing prostate epithelial cells.
Journal of Andrology, 21:367-375, 2000
(42) Guy L., Begin L.R., Oligny L.L., Brock G.B., Chevalier S., Aprikian A.G.
Searching for an intrinsic neuroendocrine cell in the kidney
Pathology Research and Practice, 195: 1999
(41) Guy L., Begin L.R., Al-Othman K., Chevalier S., Aprikian A.G.
Neuroendocrine cells of the veru montanum
British Journal of Urology, 82:738-743, 1998
(40) Ecles R.A., Durocher F., Edwards S., Teare D., Badzioch M., Hhamoudi R., Gill S., Biggs P., Dearnely D., Ardern-Jones A., Dowe A., Shearer R., McLennan R.W., Norman R., Ghadirian P., Aprikian A.G., Ford D., Amos C., King T., Labrie F., Simard J., Narod S., Eastou D., Foulkes W. Linkage analysis of chromosome 1q markers in 136 prostate cancer families
The American Journal Human Genetics, 62:653-658, 1998
(39) Karakiewicz P.I., Zini A., Meshref A.W., Bazinet M., Aprikian A.G., Elhilali M.
Population-based patterns of radical retropubic prostatectomy use
Urology, 52:219-223, 1998
(38) Karakiewicz P.I., Bazinet M., Aprikian A.G., Tanguay S., Elhilali M.
30-day mortality rates and cumulative survival after radical retropubic prostatectomy
Urology, 52:1041-1046, 1998
(37) Begin L.R., Guy L., Jacobson S.A., Aprikian A.G.
Renal carcinoid and horseshoe kidney: A frequent association of two rare entities
Journal of Surgical Oncology, 68:113-119, 1998
(36) Bazinet M., Zheng W., Begin L.R., Aprikian A.G., Karakiewicz P., Elhilali M.
morphological changes induced by neo-adjuvant androgen ablation may result in underdetection
of positive surgical margins and capsular involvement by prostatic adenocarcinoma
Urology, 49:721-725, 1997
(35) Aprikian A.G., Tremblay L., Han K., Chevalier S.
Bombesin stimulates the motility of human prostate cancer cells via the tyrosine phosphorylation
of focal adhesion kinase and integrin-associated proteins
International Journal of Cancer, 72:498-504, 1997
(34) Karakiewicz P.I., Bazinet M., Meshref A.W., Aprikian A.G., Trudel C., Aronson S., Nachabe M., Peloquin F., Goyal M.S., Begin L., Elhilali M.
Value of repeat ultrasonic prostatic biopsies following negaitive digitally directed biopsy
Canadian Journal of Urology, 4:289-292, 1997
(33) Fair W.R., Cookson M.S., Stroumbakis N., Cohen D., Aprikian A.G., Wang Y., Russo P.,
Soloway S.M., Sogani P., Sheinfeld J., Herr H., Begg C.B., Heston W.D., Reuter V.E.
The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment
of prostatic cancer: Memorial Sloan-Kettering Cancer Center results
Urology, 49:46-55, 1997
(32) Karakiewicz P., Aprikian A.G., Bazinet M., Elhilali M.
Patient attitudes towards treatment related impotence in men undergoing prostate cancer
early detection
Urology, 50:704-709, 1997
(31) Karakiewicz P.I., Bazinet M., Aprikian A.G., Trudel C., Aronson S., Nachabe M., Peloquin F., Dessureault J., Goyal M.S., Begin L.R., Elhilali M.
Outcome of sextant biopsy according to gland volume
Urology 49:55-59, 1997
(30) Han K., Viallet J., Chevalier S., Zheng W., Bazinet M., Aprikian A.G.
Characterization of intracellular calcium mobilization by bombesin-related neuropeptides in PC-3 human prostate cancer cells
Prostate, 31:53-60, 1997
(29) Bazinet M., Karakiewicz P.I., Aprikian A.G., Trudel C., Aronson S., Nachabe M., Peloquin F., Dessureault J., Goyal M., Zheng W., Begin L.R., Elhilali M.
Value of systematic transition zone biopsies in early detection of prostate cancer
Journal of Urology, 155:605-606, 1996
(28) Aprikian A.G., Han K., Chevalier S., Bazinet M., Viallet J.
Bombesin induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human androgen-insensitive prostate cancer cell lines
Journal of Molecular Endocrinology, 16:297-306, 1996
(27) Bazinet M., Karakiewicz P., Aprikian A.G., Trudel C., Peloquin F., Dessureault J., Elhilali M. Reassessment of nonplanimetric transrectal ultrasound prostatic volume estimates
Urology, 47:857-862, 1996
(26) Tremblay L., Hauck W., Aprikian A.G., Begin L.R., Chapdelaine A., Chevalier S.
Focal adhesion kinase (pp125fak) expression, activation and association with paxillin and p50csk
in human metastatic prostate carcinoma
International Journal of Cancer, 68:164-171, 1996
(25) Brenner P.C., Herr H.W., Morse M.J., Sheinfeld J., Aprikian A.G., Bosl G.J., Motzer R.J.,
Bajorin D.F., Schantz S., Fair W.R., Burt M.
Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis
Journal of Clinical Oncology, 14:1765-1769, 1996
(24) Karakiewicz P., Aprikian A.G., Meshref A.W., Bazinet M.
Computer-assisted comparative analysis of four-sector versus six-sector biopsies of the prostate
Urology, 48:747-750, 1996
(23) Karakiewicz P., Bazinet M., Aprikian A.G., Trudel C., Aronson S., Peloquin F., Dessureault J., Nachabe M., Goyal M., Begin L.R., Elhilali M.
Analysis of gland volume effect on the performance of PSA density in early detection of non-
palpable, isoechoic prostate cancer
Canadian Journal of Urology, 3:212-220, 1996
(22) Bazinet M., Karakiewicz P.I., Aprikian A.G., Trudel. C., Aronson,S., Peloquin F., Dessureault J.,
Goyal M.S., Zheng W., Begin L.R., Elhilali M.
Complications of ultrasound-guided prostate biospy of the peripheral zone and transition zone
Urologic Oncology, 2:2, 65-69, 1996
(21) Aaron L., Aprikian A.G.
Parapelvic cyst causing obstruction of the pelvocalyceal system in an asymptomatic nineteen
year-old male
Progres en Urologie, 5:95-98, 1995
(20) Brenner P.C., Rettig W.J., Sanz-Moncasi M.P., Reuter V.E., Aprikian A.G., Old L.J.,
Fair W.R., Garin-Chesa, P.
Tag 72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49
Journal of Urology, 153:1575-1579, 1995
(19) Meshref A.W., Bazinet M., Trudel C., Aronson S., Peloquin F., Nachabe M., Dessureault J.,
Aprikian A.G., Begin L.R., Elhilali M.
The role of prostate specific antigen density after applying age specific prostate specific antigen reference ranges
Urology, 45:972-979, 1995
(18) Aprikian A.G., Bazinet M., Meshref A., Plante M., Trudel C., Aronson S., Nachabe M.,
Peloquin F., Dessureault J., Narod S., Begin L., Elhilali M.
Family history and the risk of prostatic carcinoma in a high risk group of urologic patients
Journal of Urology, 154:404-406, 1995
(17) Aprikian A.G., Atef A.R., Duguid W.P., Bazinet M., Laplante M., Reid E.C., Macisaac S.G.,
Ackman C.F.D., Elhilali M.
Survival after pelvic lymphadenectomy and radical cystectomy for patients with lymph node metastatic transitional cell carcinoma of the bladder
Oncology Reports, 2:633-635, 1995
(16) Bazinet M., Hamdy S.F., Begin L.R., Aprikian A.G., Fair W.R., Wright G.L. jr
Monoclonal antibody PD-41 recognizes a prostate cancer associated antigen whose expression increases in metastases and following hormonal therapy
International Journal of Oncology, 7, 1995
(15) Doran P., Aprikian A.G., Shuster J., Green L.
Case Report: A 25 year-old Man with severe non-hemorrhagic intraoperative shock
McGill Journal of Medicine, 1:84-86. 1995
(14) Sun S., Narod S., Aprikian A.G., Ghadirian P., Labrie F.
Androgen receptor and familial prostate cancer
Nature Medicine, 1:6, 1995
(13) Zhang Z-F, Sarkis A.S., Cordon-Cardo C., Dalbagni G., Melamed J., Aprikian A.G.,
Pollack D., Herr H.W., Fair W.R., Reuter V.E., Begg C.
Cigarette smoking and nuclear overexpression of p53 protein in superficial transitional cell carcinoma of the bladder
Cancer Epidemiology Biomarkers and Prevention, 3:19-24, 1994
(12) Hamdy S.M., Aprikian A.G., Begin L.R., Fair W.R., Bazinet M.
Ras p-21 overexpression is a late event in prostate cancer
International Journal of Oncology 4:627-631, 1994
(11) Aprikian A.G., Guan Z., Nielson K., Kiruluta G.
The use of gastric muscularis in creating a urinary sphincter
Urology, 43:267-272, 1994
(10) Aprikian A.G., Cordon-Cardo C., Fair W.R., Zhang Z.F., Bazinet M., Hamdy S.M., Reuter V.E.
Neuroendocrine differentiation in metastatic prostatic adenocarcinoma
Journal of Urology, 151:914-919, 1994
(9) Aprikian A.G., Sarkis A., Fair W.R., Zhang Z.F., Fuks Z., Cordon-Cardo C.
Immunohistochemical determination of p53 nuclear accumulation in prostatic adenocarcinoma
Journal of Urology, 151:1276-1280, 1994
(8) Zhang Z.F., Aprikian A.G., Sarkis A.S., Zeng Z., Cordon-Cardo C., Fair W.R., Begg C.
Factors associated with p53 nuclear accumulation in prostatic adenocarcinoma
International Journal of Oncology, 4:897-902, 1994
(7) Aprikian A.G., Zhang Z.F., Fair W.R.
Prostatic adenocarcinoma in men less than 50 years old: A retrospective review of 151 cases
Cancer, 74:1768-77, 1994
(6) Armas O.A., Aprikian A.G., Melamed J., Cordon-Cardo C., Cohen D.W., Erlandson R.,
Fair W.R., Reuter V.E.
Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on
clinically localized prostatic adenocarcinoma.
American Journal of Surgical Pathology, 18:979-991, 1994
(5) Aprikian A.G., Herr H.W., Bajorin D., Bosl. G.
Resection of residual masses and limited retroperitoneal lymphadenectomy after chemotherapy
in patients with metastatic testicular nonseminomatous germ cell tumors
Cancer, 74:1329-1334, 1994
(4) Aprikian A.G., Fair W.R., Reuter V.E., Sogani P., Herr H., Russo P., Sheinfeld J.
Experience with neoadjuvant diethylstilbestrol and radical prostatectomy in locally advanced
prostate cancer
British Journal of Urology, 74:630-636, 1994
(3) Aprikian A.G., Cordon-Cardo C., Fair W.R., Reuter V.E.
Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma
Cancer, 71:3952-3965, 1993
(2) Aprikian A.G., Berardinucci G., Pike J., Kiruluta G.
Experience with the artificial urinary sphincter AS-800 in children with myelomeningocele
Canadian Journal of Surgery, 35 (4):396-400, 1992
(1) Aprikian A.G., Jothy S., Elhilali M.M.
Congenital keratinizing squamous epithelium of the entire urinary tract
Journal of Urology 146:423-425, 1991
INVITED REVIEW ARTICLES OR EDITORIALS:
(1) Aprikian, A.G.
PSA for prostate cancer detection: In serum, urine or both?
Canadian Urology Asoociation Journal; 1:382, 2007
(2) Fradet Y., Aprikian A.G., Dranitsaris G., Siemens R., Tsihlias J., Fleshner N.
Does prolonging the time interval to bladder cancer surgery affect long-term cancer control: a systematic review of the literature.
Canadian Journal of Urology 13: Supplement 3, 37-47, 2006
(3) Saad, F., Aprikian, A.G.
Review of a new molecular urine test for prostate cancer detection: uPM3
The Journal of New Developments in Clinical Medicine, 22:115-120, 2004
(4) Aprikian A.G.
Risk stratification in clinically localized prostate cancer
Canadian Journal of Urology, 9,supplement 1:18-20, 2002
(5) Aprikian A.G., Han K., Guy L., Landry F., Begin L., Chevalier S.
Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of
neuropeptidesin the progression of human prostate cancer
Prostate, 8:52-61, 1998
(6) Karakiewicz P.I., Aprikian A.G.
Prostate cancer: Diagnostic tools for early detection
Canadian Medical Association Journal, 159:1139-1146, 1998
(7) Aprikian A.G.
Neuroendocrine differentiation of prostate cancer and the role of bombesin
Prostate Cancer and Prostatic Diseases, 1: S31, 1998
(8) Aprikian A.G., Tanguay S.
The evolving role of radical surgery in the management of regionally advanced transitional
cell carcinoma of the bladder
Canadian Journal of Urology, 5:643-651, 1998
Canadian Journal of Urology, 1997
(10) Aprikian A.G.
Molecular basis for total androgen blockade
Canadian Journal of Urology, 3:235-239, 1996
(11) Aprikian A.G.
Current concepts regarding the management of hormone-refractory prostate cancer
Urologic Oncology Update 1995, 1-6, 1995
(12) Fair W.R., Aprikian A.G., Cohen D., Sogani P.S., Reuter V.E.
The use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer
Clinical and Investigative Medicine, 16:516-522, 1994
(13) Aprikian A.G.
The clinical and biological significance of neuroendocrine differentiation of prostatic adenocarcinoma
Canadian Prostate Update, 1:6, 1994
(14) Fair W.R., Aprikian A.G., Sogani P., Reuter V.E., Whitmore W.F.
The role of neoadjuvant hormonal manipulation in localized prostatic cancer
Cancer 71:1031-1038, 1993
(15) Aprikian A.G., Sarkis A., Reuter V.E., Cordon-Cardo C., Sheinfeld J.
Biologic markers in transitional cell carcinoma of the bladder; Current concepts
Seminars in Urology 11 (3):137-144, 1993
(16) Aprikian A.G., Fair W.R.
Attaching clinical relevance to chemotherapy trials for advanced bladder cancer
Contemporary Urology 4:13-22, 1992
(17) Aprikian A.G., Sheinfeld J.
Cell surface tumor markers in bladder cancer
The Report on Urologic Techniques 2 (7): 65-69, 1992
(18) Fair W.R., Aprikian A.G., Reuter V.E.
Neoadjuvant hormonal manipulation: a strategy for chemoprevention trials
Journal of Cellular Biochemistry, 16H:118-121, 1992
Other Publications or Contributions:
(1) Hosted Prime Minister Harper at the MUHC for Canadian Initiative on Cancer 2006
(2) Interview by A. Scully on PBS program Organs on prostate cancer 2007
(3) The Gazette, La Presse, Le Devoir interviews on delays in bladder cancer surgery across Quebec 2006
(4) Aprikian A.G. 2003
Management of clinically localized and locally advanced prostate cancer
Continuing medical education-CD-ROM
(5) Member of Organizing Committee 2001
1700th Anniversary of Armenian Christianity
Celebration Concert, Notre Dame Basilica, Montreal
(6) Aprikian A.G. 1997
“Turning off the drip”, interview on BPH
Chatelaine, August 1997, p 96
(7) Aprikian A.G., Saad, F. 1996
Benign Prostatic Hyperplasia Educational CD-ROM for the general practitioner
Revised April 1, 2008
